MERCURY LABORATORIES
|
MERCURY LABORATORIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 47.12 | 46.49 | 29.68 | 44.48 | 26.90 |
| CEPS(Rs) | 70.58 | 67.18 | 50.12 | 60.48 | 42.48 |
| DPS(Rs) | 3.50 | 3.50 | 3.50 | 3.50 | 2.00 |
| Book NAV/Share(Rs) | 423.65 | 380.24 | 335.89 | 307.46 | 266.48 |
| Tax Rate(%) | 18.30 | 25.06 | 29.25 | 32.51 | 25.43 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.95 | 11.38 | 12.07 | 13.98 | 10.77 |
| EBIT Margin(%) | 9.67 | 10.36 | 9.46 | 12.46 | 8.99 |
| Pre Tax Margin(%) | 9.16 | 9.88 | 8.69 | 11.53 | 7.56 |
| PAT Margin (%) | 7.48 | 7.41 | 6.15 | 7.78 | 5.64 |
| Cash Profit Margin (%) | 11.21 | 10.70 | 10.38 | 10.58 | 8.90 |
| Performance Ratios | |||||
| ROA(%) | 8.56 | 8.81 | 5.57 | 8.77 | 5.68 |
| ROE(%) | 11.72 | 12.98 | 9.23 | 15.50 | 10.59 |
| ROCE(%) | 13.61 | 16.19 | 12.26 | 20.56 | 13.25 |
| Asset Turnover(x) | 1.14 | 1.19 | 0.91 | 1.13 | 1.01 |
| Sales/Fixed Asset(x) | 1.69 | 1.73 | 1.38 | 1.77 | 1.59 |
| Working Capital/Sales(x) | 2.81 | 2.98 | 2.97 | 3.62 | 3.48 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.59 | 0.58 | 0.73 | 0.57 | 0.63 |
| Receivable days | 104.38 | 92.32 | 123.77 | 108.21 | 119.27 |
| Inventory Days | 31.66 | 33.14 | 37.61 | 28.38 | 39.17 |
| Payable days | 103.82 | 128.22 | 225.52 | 178.16 | 210.82 |
| Valuation Parameters | |||||
| PER(x) | 17.66 | 12.59 | 16.34 | 14.45 | 10.45 |
| PCE(x) | 11.79 | 8.71 | 9.68 | 10.62 | 6.62 |
| Price/Book(x) | 1.96 | 1.54 | 1.44 | 2.09 | 1.05 |
| Yield(%) | 0.42 | 0.60 | 0.72 | 0.54 | 0.71 |
| EV/Net Sales(x) | 1.29 | 0.91 | 0.97 | 1.16 | 0.67 |
| EV/Core EBITDA(x) | 9.60 | 6.64 | 7.23 | 7.58 | 5.47 |
| EV/EBIT(x) | 13.30 | 8.75 | 10.29 | 9.28 | 7.46 |
| EV/CE(x) | 1.72 | 1.34 | 0.90 | 1.21 | 0.68 |
| M Cap / Sales | 1.32 | 0.93 | 1.00 | 1.12 | 0.59 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 0.30 | 30.06 | -15.56 | 19.79 | 3.15 |
| Core EBITDA Growth(%) | -1.66 | 31.82 | -25.45 | 49.26 | 3.68 |
| EBIT Growth(%) | -6.45 | 42.43 | -35.90 | 66.14 | 0.15 |
| PAT Growth(%) | 1.35 | 56.62 | -33.27 | 65.34 | 13.82 |
| EPS Growth(%) | 1.35 | 56.62 | -33.27 | 65.34 | 13.82 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.11 | 0.12 | 0.13 | 0.19 | 0.22 |
| Current Ratio(x) | 3.08 | 2.78 | 2.24 | 2.01 | 2.09 |
| Quick Ratio(x) | 2.60 | 2.30 | 1.81 | 1.73 | 1.73 |
| Interest Cover(x) | 19.07 | 21.57 | 12.28 | 13.33 | 6.30 |
| Total Debt/Mcap(x) | 0.06 | 0.08 | 0.09 | 0.09 | 0.21 |
Compare Financial Ratios of peers of MERCURY LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MERCURY LABORATORIES | ₹108.2 Cr | -2.2% | -2.6% | 17.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹436,103.0 Cr | 1% | 0.7% | 47.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹153,540.0 Cr | -1.1% | -5.8% | 61.7% | Stock Analytics | |
| CIPLA | ₹119,196.0 Cr | 0.3% | -1.8% | 19.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,752.0 Cr | 6% | 11.8% | 20.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹97,041.2 Cr | -1.5% | -0.1% | 47% | Stock Analytics | |
MERCURY LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MERCURY LABORATORIES | -2.2% |
-2.6% |
17.5% |
| SENSEX | -2.7% |
-0.8% |
9.9% |
You may also like the below Video Courses
